Bi-functional SuperKine ImmunoTherapies platform that fuses IL-2, IL-4, and/or IL-13 Superkines with proteins, antibodies, checkpoint inhibitors, or other Superkines to create dual-function molecules for treatment of cancers, including immunologically cold tumors

Targets: IL-2Rβ, PD-1, IL-4R, IL-13Rα2, IL-2

T-MASK

Targeted Metalloprotease Activated SuperKine platform — conditionally activates IL-2 Superkine payloads via tumor-associated MMP cleavage and proximity-dependent unmasking in the tumor microenvironment; focus on solid tumors

Targets: MMP, IL-13Rα2

Biotech Distilled coverage (5)

2026-05-22 UPDATE: Medicenna Therapeutics (MDNAF) - The Prospectus Supplement Drops, and a Sorbie Wrinkle Appears 🔒 Paid
2026-05-19 UPDATE: Medicenna Therapeutics (MDNAF) - The Pricing Print Lands, and the Tape Tells You Everything 🔒 Paid
2026-05-14 UPDATE: Medicenna Therapeutics (MDNAF) - The Dilution Headline Lands 🔒 Paid
2026-04-27 UPDATE: Medicenna Therapeutics (MDNAF) - The Science Wins, the Cash Cliff Looms Closer 🔒 Paid
2026-03-20 Medicenna Therapeutics (MDNAF) - Scientific Deep Dive for MDNA11 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.